Yahoo Finance5d
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
PARAMUS, N.J., March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that ...
Capricor Therapeutics receives FDA acceptance of BLA for deramiocel
NS Pharma, a subsidiary of Nippon Shinyaku Co., announced that acceptance has been received by Capricor Therapeutics (CAPR) from the U.S. FDA ...
pharmaphorum2d
Nippon Shinyaku’s DMD drug fails confirmatory trial
The Japanese group’s NS Pharma subsidiary has revealed that Viltepso (viltolarsen) missed its primary objective in the confirmatory RACER53 trial, and was unable to distinguish itself from ...
Finanznachrichten17d
DelveInsight Business Research, LLP: The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight
The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...
Investing11d
Capricor Therapeutics stock rises on FDA priority review
"With shares trading at an EV of just $680M at last night’s close despite $1B+ sales potential in the US alone and attractive terms with commercial partner NS Pharma, we expect the stock to ...
pharmaphorum5d
FDA okays Italfarmaco’s non-steroidal DMD therapy Duvyzat
Along with Sarepta and NS Pharma’s exon-skipping therapies, which together cater for approximately a third of patients, Sarepta also has FDA approval for a gene therapy, Elevidys ...
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.